{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T02:26:16Z","timestamp":1785291976435,"version":"3.55.0"},"reference-count":63,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,18]],"date-time":"2025-11-18T00:00:00Z","timestamp":1763424000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,12,15]],"date-time":"2025-12-15T00:00:00Z","timestamp":1765756800000},"content-version":"vor","delay-in-days":27,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000025","name":"U.S. Department of Health & Human Services | NIH | National Institute of Mental Health","doi-asserted-by":"publisher","award":["ZIAMH002857"],"award-info":[{"award-number":["ZIAMH002857"]}],"id":[{"id":"10.13039\/100000025","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000025","name":"U.S. Department of Health & Human Services | NIH | National Institute of Mental Health","doi-asserted-by":"publisher","award":["ZIAMH002857"],"award-info":[{"award-number":["ZIAMH002857"]}],"id":[{"id":"10.13039\/100000025","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000025","name":"U.S. Department of Health & Human Services | NIH | National Institute of Mental Health","doi-asserted-by":"publisher","award":["ZIAMH002857"],"award-info":[{"award-number":["ZIAMH002857"]}],"id":[{"id":"10.13039\/100000025","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000025","name":"U.S. Department of Health & Human Services | NIH | National Institute of Mental Health","doi-asserted-by":"publisher","award":["ZIAMH002857"],"award-info":[{"award-number":["ZIAMH002857"]}],"id":[{"id":"10.13039\/100000025","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000025","name":"U.S. Department of Health & Human Services | NIH | National Institute of Mental Health","doi-asserted-by":"publisher","award":["ZIAMH002857"],"award-info":[{"award-number":["ZIAMH002857"]}],"id":[{"id":"10.13039\/100000025","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000025","name":"U.S. Department of Health & Human Services | NIH | National Institute of Mental Health","doi-asserted-by":"publisher","award":["ZIAMH002857"],"award-info":[{"award-number":["ZIAMH002857"]}],"id":[{"id":"10.13039\/100000025","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000025","name":"U.S. Department of Health & Human Services | NIH | National Institute of Mental Health","doi-asserted-by":"publisher","award":["ZIAMH002857"],"award-info":[{"award-number":["ZIAMH002857"]}],"id":[{"id":"10.13039\/100000025","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000025","name":"U.S. Department of Health & Human Services | NIH | National Institute of Mental Health","doi-asserted-by":"publisher","award":["ZIAMH002857"],"award-info":[{"award-number":["ZIAMH002857"]}],"id":[{"id":"10.13039\/100000025","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000025","name":"U.S. Department of Health & Human Services | NIH | National Institute of Mental Health","doi-asserted-by":"publisher","award":["ZIAMH002857"],"award-info":[{"award-number":["ZIAMH002857"]}],"id":[{"id":"10.13039\/100000025","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000025","name":"U.S. Department of Health & Human Services | NIH | National Institute of Mental Health","doi-asserted-by":"publisher","award":["ZIAMH002857"],"award-info":[{"award-number":["ZIAMH002857"]}],"id":[{"id":"10.13039\/100000025","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000025","name":"U.S. Department of Health & Human Services | NIH | National Institute of Mental Health","doi-asserted-by":"publisher","award":["ZIAMH002857"],"award-info":[{"award-number":["ZIAMH002857"]}],"id":[{"id":"10.13039\/100000025","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000025","name":"U.S. Department of Health & Human Services | NIH | National Institute of Mental Health","doi-asserted-by":"publisher","award":["ZIAMH002857"],"award-info":[{"award-number":["ZIAMH002857"]}],"id":[{"id":"10.13039\/100000025","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000025","name":"U.S. Department of Health & Human Services | NIH | National Institute of Mental Health","doi-asserted-by":"publisher","award":["ZIAMH002857"],"award-info":[{"award-number":["ZIAMH002857"]}],"id":[{"id":"10.13039\/100000025","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000025","name":"U.S. Department of Health & Human Services | NIH | National Institute of Mental Health","doi-asserted-by":"publisher","award":["ZIAMH002857"],"award-info":[{"award-number":["ZIAMH002857"]}],"id":[{"id":"10.13039\/100000025","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002790","name":"Canadian Network for Research and Innovation in Machining Technology, Natural Sciences and Engineering Research Council of Canada","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002790","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Transl Psychiatry"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Treatment-resistant depression (TRD) is associated with worse clinical outcomes and longer course of illness. However, TRD is more difficult to model in animal phenotypes, suggesting that other experimental and translational models must be considered to properly address and research novel therapeutics. Reelin, an endogenous glycoprotein downregulated in depression, has shown rapid antidepressant-like effects akin to those of the N-methyl-D-aspartate receptor (NMDAR) antagonist ketamine. Interestingly, the antidepressant-like effects of both ketamine and reelin affect mechanistic target of rapamycin complex 1 (mTORC1) activity and that of its related downstream signalers. (2\u2009\n                    <jats:italic>R<\/jats:italic>\n                    ,6\u2009\n                    <jats:italic>R<\/jats:italic>\n                    )-hydroxynorketamine (HNK) is a major metabolite of ketamine that, at therapeutic levels, appears to activate mTORC1 without antagonizing NMDARs. To model the effects of (2\u2009\n                    <jats:italic>R<\/jats:italic>\n                    ,6\u2009\n                    <jats:italic>R<\/jats:italic>\n                    )-HNK and reelin on neurons from TRD participants, induced pluripotent stem cells (iPSCs) were reprogrammed from peripheral blood mononuclear cells collected from five females with TRD (mean=40.2\u2009yrs) and then differentiated into cortical neurons. In iPSC-derived neurons from TRD participants, 50\u2009nM reelin and 1\u2009\u00b5M (2\u2009\n                    <jats:italic>R<\/jats:italic>\n                    ,6\u2009\n                    <jats:italic>R<\/jats:italic>\n                    )-HNK had similar effects on the protein expression of GluA1, PSD-95, Dab1, Synapsin I, and p-ERK, with concentration-dependent increases observed at one hour that significantly decreased by 24\u2009h. RNA sequencing revealed similar changes in gene expression between 50\u2009nM reelin and 1\u2009\u00b5M (2\u2009\n                    <jats:italic>R<\/jats:italic>\n                    ,6\u2009\n                    <jats:italic>R<\/jats:italic>\n                    )-HNK at one hour, although only reelin upregulated mTORC1 signaling. While this work remains preliminary, the results suggest that iPSC-derived neurons could provide a valuable in vitro model to study TRD and hold promise for evaluating novel therapeutics such as (2\u2009\n                    <jats:italic>R<\/jats:italic>\n                    ,6\u2009\n                    <jats:italic>R<\/jats:italic>\n                    )-HNK and reelin.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Clinicaltrials.gov<\/jats:bold>\n                    : NCT02484456\n                  <\/jats:p>","DOI":"10.1038\/s41398-025-03724-6","type":"journal-article","created":{"date-parts":[[2025,11,18]],"date-time":"2025-11-18T02:36:09Z","timestamp":1763433369000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Response of iPSC-derived neurons from individuals with treatment-resistant depression to (2\u2009R,6\u2009R)-hydroxynorketamine and reelin: an exploratory study"],"prefix":"10.1038","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2986-3179","authenticated-orcid":false,"given":"Jenessa N.","family":"Johnston","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peixiong","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3809-9451","authenticated-orcid":false,"given":"Bashkim","family":"Kadriu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nirmala","family":"Akula","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brandi","family":"Quintanilla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shiyong","family":"Peng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3959-1077","authenticated-orcid":false,"given":"Greg H.","family":"Jones","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6323-4969","authenticated-orcid":false,"given":"Anton","family":"Schulmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8387-4720","authenticated-orcid":false,"given":"Mani","family":"Yavi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ioline D.","family":"Henter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9469-305X","authenticated-orcid":false,"given":"Francis J.","family":"McMahon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa E.","family":"Kalynchuk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"Jr.","given":"Carlos A.","family":"Zarate","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4614-9495","authenticated-orcid":false,"given":"Hector J.","family":"Caruncho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,18]]},"reference":[{"key":"3724_CR1","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.ejphar.2014.10.063","volume":"753","author":"BJ Caldarone","year":"2015","unstructured":"Caldarone BJ, Zachariou V, King SL. Rodent models of treatment-resistant depression. Eur J Pharm. 2015;753:51\u201365.","journal-title":"Eur J Pharm"},{"key":"3724_CR2","doi-asserted-by":"crossref","first-page":"3473","DOI":"10.1007\/s00213-015-4034-7","volume":"232","author":"P Willner","year":"2015","unstructured":"Willner P, Belzung C. Treatment-resistant depression: are animal models of depression fit for purpose?. Psychopharmacology (Berl). 2015;232:3473\u201395.","journal-title":"Psychopharmacology (Berl)"},{"key":"3724_CR3","doi-asserted-by":"crossref","first-page":"e027574","DOI":"10.1136\/bmjopen-2018-027574","volume":"9","author":"K Shinohara","year":"2019","unstructured":"Shinohara K, Efthimiou O, Ostinelli EG, Tomlinson A, Geddes JR, Nierenberg AA, et al. Comparative efficacy and acceptability of antidepressants in the long-term treatment of major depression: protocol for a systematic review and networkmeta-analysis. BMJ Open. 2019;9:e027574.","journal-title":"BMJ Open"},{"key":"3724_CR4","doi-asserted-by":"crossref","first-page":"403","DOI":"10.3390\/cells8050403","volume":"8","author":"MX Doss","year":"2019","unstructured":"Doss MX, Sachinidis A. Current challenges of iPSC-based disease modeling and therapeutic implications. Cells. 2019;8:403.","journal-title":"Cells"},{"key":"3724_CR5","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1007\/s00441-017-2713-x","volume":"371","author":"L Li","year":"2018","unstructured":"Li L, Chao J, Shi Y. Modeling neurological diseases using iPSC-derived neural cells: iPSC modeling of neurological diseases. Cell Tissue Res. 2018;371:143\u201351.","journal-title":"Cell Tissue Res"},{"key":"3724_CR6","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1007\/s00702-020-02197-9","volume":"127","author":"RV McNeill","year":"2020","unstructured":"McNeill RV, Ziegler GC, Radtke F, Nieberler M, Lesch K-P, Kittel-Schneider S. Mental health dished up\u2014the use of iPSC models in neuropsychiatric research. J Neural Transm (Vienna). 2020;127:1547\u201368.","journal-title":"J Neural Transm (Vienna)"},{"key":"3724_CR7","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1038\/s41380-023-01990-8","volume":"28","author":"Y Hong","year":"2023","unstructured":"Hong Y, Yang Q, Song H, Ming JL. Opportunities and limitations for studying neuropsychiatric disorders using patient-derived induced pluripotent stem cells. Mol Psychiatry. 2023;28:1430\u20139.","journal-title":"Mol Psychiatry"},{"key":"3724_CR8","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1038\/s41380-019-0363-y","volume":"24","author":"KC Vadodaria","year":"2019","unstructured":"Vadodaria KC, Ji Y, Skime M, Paquola A, Nelson T, Hall-Flavin D, et al. Serotonin-induced hyperactivity in SSRI-resistant major depressive disorder patient-derived neurons. Mol Psychiatry. 2019;24:795\u2013807.","journal-title":"Mol Psychiatry"},{"key":"3724_CR9","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1038\/s41380-019-0377-5","volume":"24","author":"KC Vadodaria","year":"2019","unstructured":"Vadodaria KC, Ji Y, Skime M, Paquola AC, Nelson T, Hall-Flavin D, et al. Altered serotonergic circuitry in SSRI-resistant major depressive disorder patient-derived neurons. Mol Psychiatry. 2019;24:808\u201318.","journal-title":"Mol Psychiatry"},{"key":"3724_CR10","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1038\/mp.2017.255","volume":"23","author":"P Zanos","year":"2018","unstructured":"Zanos P, Gould TD. Mechanisms of ketamine action as an antidepressant. Mol Psychiatry. 2018;23:801\u201311.","journal-title":"Mol Psychiatry"},{"key":"3724_CR11","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.neuron.2019.03.013","volume":"102","author":"RS Duman","year":"2019","unstructured":"Duman RS, Sanacora G, Krystal JH. Altered connectivity in depression: GABA and glutamate neurotransmitter deficits and reversal by novel treatments. Neuron. 2019;102:75\u201390.","journal-title":"Neuron"},{"key":"3724_CR12","doi-asserted-by":"crossref","DOI":"10.1016\/j.neuropharm.2023.109422","volume":"226","author":"JN Johnston","year":"2023","unstructured":"Johnston JN, Kadriu B, Allen J, Gilbert JR, Henter ID, Zarate CAJ. Ketamine and serotonergic psychedelics: An update on the mechanisms and biosignatures underlying rapid-acting antidepressant treatment. Neuropharmacology. 2023;226:109422.","journal-title":"Neuropharmacology"},{"key":"3724_CR13","doi-asserted-by":"crossref","first-page":"4144","DOI":"10.1038\/s41380-022-01673-w","volume":"27","author":"J Bonaventura","year":"2022","unstructured":"Bonaventura J, Gomez JL, Carlton ML, Lam S, Sanchez-Soto M, Morris PJ, et al. Target deconvolution studies of (2R,6R)-hydroxynorketamine: an elusive search. Mol Psychiatry. 2022;27:4144\u201356.","journal-title":"Mol Psychiatry"},{"key":"3724_CR14","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1038\/nature17998","volume":"533","author":"P Zanos","year":"2016","unstructured":"Zanos P, Moaddel R, Morris PJ, Georgiou P, Fischell J, Elmer GI, et al. NMDAR inhibition-independent antidepressant actions of ketamine metabolites. Nature. 2016;533:481\u20136.","journal-title":"Nature"},{"key":"3724_CR15","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.1002\/cpt.3391","volume":"116","author":"SM Raja","year":"2024","unstructured":"Raja SM, Guptill JT, Mack M, Peterson M, Byard S, Twieg R, et al. A phase 1 assessment of the safety, tolerability, pharmacokinetics and pharmacodynamics of (2R,6R)-Hydroxynorketamine in healthy volunteers. Clin Pharm Ther. 2024;116:1314\u201324.","journal-title":"Clin Pharm Ther"},{"key":"3724_CR16","volume":"118","author":"J-W Kim","year":"2021","unstructured":"Kim J-W, Herz J, Kavalali ET, Monteggia LM. A key requirement for synaptic reelin signaling in ketamine-mediated behavioral and synaptic action. Proc Natl Acad Sci. 2021;118:e2103079118.","journal-title":"Proc Natl Acad Sci"},{"key":"3724_CR17","doi-asserted-by":"crossref","first-page":"3209","DOI":"10.1097\/00001756-200110290-00014","volume":"12","author":"SH Fatemi","year":"2001","unstructured":"Fatemi SH, Kroll JL, Stary JM. Altered levels of reelin and its isoforms in schizophrenia and mood disorders. Neuroreport. 2001;12:3209\u201315.","journal-title":"Neuroreport"},{"key":"3724_CR18","doi-asserted-by":"publisher","unstructured":"Johnston JN, Allen J, Shkolnikov I, Sanchez-Lafuente CL, Reive BS, Scheil K et al. Reelin rescues behavioral, electrophysiological, and molecular metrics of a chronic stress phenotype in a similar manner to ketamine. eNeuro 2023; 10. https:\/\/doi.org\/10.1523\/ENEURO.0106-23.2023.","DOI":"10.1523\/ENEURO.0106-23.2023"},{"key":"3724_CR19","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2020.559627","volume":"11","author":"JN Johnston","year":"2020","unstructured":"Johnston JN, Thacker JS, Desjardins C, Kulyk BD, Romay-Tallon R, Kalynchuk LE, et al. Ketamine rescues hippocampal reelin expression and synaptic markers in the repeated-corticosterone chronic stress paradigm. Front Pharm. 2020;11:559627.","journal-title":"Front Pharm"},{"key":"3724_CR20","doi-asserted-by":"crossref","DOI":"10.1016\/j.pnpbp.2024.110998","volume":"132","author":"KK Scheil","year":"2024","unstructured":"Scheil KK, S\u00e1nchez-Lafuente CL, Reive BS, Halvorson CS, Floyd J, Reid HM, et al. Time-dependent antidepressant-like effects of reelin and ketamine in the repeated-corticosterone model of chronic stress. Prog Neuropsychopharmacol Biol Psychiatry. 2024;132:110998.","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"3724_CR21","doi-asserted-by":"crossref","DOI":"10.1016\/j.drudis.2023.103518","volume":"28","author":"JN Johnston","year":"2023","unstructured":"Johnston JN, Greenwald MS, Henter ID, Kraus C, Mkrtchian A, Clark NG, et al. Inflammation, stress and depression: an exploration of ketamine\u2019s therapeutic profile. Drug Discov Today. 2023;28:103518.","journal-title":"Drug Discov Today"},{"key":"3724_CR22","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.3233\/JAD-240088","volume":"100","author":"BS Reive","year":"2024","unstructured":"Reive BS, Lau V, S\u00e1nchez-Lafuente CL, Henri-Bhargava A, Kalynchuk LE, Tremblay M-E, et al. The inflammation-induced dysregulation of reelin homeostasis hypothesis of Alzheimer\u2019s disease. J Alzheimers Dis. 2024;100:1099\u2013119.","journal-title":"J Alzheimers Dis"},{"key":"3724_CR23","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1038\/nri.2015.5","volume":"16","author":"AH Miller","year":"2016","unstructured":"Miller AH, Raison CL. The role of inflammation in depression: from evolutionary imperative to modern treatment target. Nat Rev Immunol. 2016;16:22\u201334.","journal-title":"Nat Rev Immunol"},{"key":"3724_CR24","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2023.112669","volume":"42","author":"A Alexander","year":"2023","unstructured":"Alexander A, Herz J, Calvier L. Reelin through the years: from brain development to inflammation. Cell Rep. 2023;42:112669.","journal-title":"Cell Rep"},{"key":"3724_CR25","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1074\/jbc.R116.766782","volume":"292","author":"CR Wasser","year":"2017","unstructured":"Wasser CR, Herz J. Reelin: neurodevelopmental architect and homeostatic regulator of excitatory synapses. J Biol Chem. 2017;292:1330\u20138.","journal-title":"J Biol Chem"},{"key":"3724_CR26","doi-asserted-by":"crossref","first-page":"3170","DOI":"10.1016\/j.celrep.2018.05.022","volume":"23","author":"C Ly","year":"2018","unstructured":"Ly C, Greb AC, Cameron LP, Wong JM, Barragan EV, Wilson PC, et al. Psychedelics promote structural and functional neural plasticity. Cell Rep. 2018;23:3170\u201382.","journal-title":"Cell Rep"},{"key":"3724_CR27","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1038\/s41380-022-01866-3","volume":"28","author":"JW Brunner","year":"2023","unstructured":"Brunner JW, Lammertse HCA, van Berkel AA, Koopmans F, Li KW, Smit AB, et al. Power and optimal study design in iPSC-based brain disease modeling. Mol Psychiatry. 2023;28:1545\u201356.","journal-title":"Mol Psychiatry"},{"key":"3724_CR28","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.1038\/mp.2017.56","volume":"23","author":"N Gunhalar","year":"2018","unstructured":"Gunhalar N, Shpak G, van der Kroeg M, Gouty-Colomer LA, Munshi ST, Lendemeijer B, et al. A simplified protocol for differentiation of electrophysiologically mature neuronal networks from human induced pluripotent stem cells. Mol Psychiatry. 2018;23:1336\u201344.","journal-title":"Mol Psychiatry"},{"key":"3724_CR29","doi-asserted-by":"crossref","DOI":"10.1016\/j.neuropharm.2022.109043","volume":"211","author":"J Allen","year":"2022","unstructured":"Allen J, Romay-Tallon R, Mitchell MA, Brymer KJ, Johnston JN, S\u00e1nchez-Lafuente CL, et al. Reelin has antidepressant-like effects after repeated or singular peripheral injections. Neuropharmacology. 2022;211:109043.","journal-title":"Neuropharmacology"},{"key":"3724_CR30","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1038\/mp.2017.241","volume":"23","author":"L Cavalleri","year":"2018","unstructured":"Cavalleri L, Pich EM, Millan MJ, Chiamulera C, Kunath T, Spano PF, et al. Ketamine enhances structural plasticity in mouse mesencephalic and human iPSC-derived dopaminergic neurons via AMPAR-driven BDNF and mTOR signaling. Mol Psychiatry. 2018;23:812\u201323.","journal-title":"Mol Psychiatry"},{"key":"3724_CR31","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1093\/bioinformatics\/bts635","volume":"29","author":"A Dobin","year":"2012","unstructured":"Dobin A, Davis CA, Schlesinger F, Drenkow J, Zaleski C, Jha S, et al. STAR: ultrafast universal RNA-seq aligner. Bioinformatics. 2012;29:15\u201321.","journal-title":"Bioinformatics"},{"key":"3724_CR32","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1093\/bioinformatics\/btt656","volume":"30","author":"Y Liao","year":"2014","unstructured":"Liao Y, Smyth GK, Shi W. featureCounts: an efficient general purpose program for assigning sequence reads to genomic features. Bioinformatics. 2014;30:923\u201330.","journal-title":"Bioinformatics"},{"key":"3724_CR33","doi-asserted-by":"crossref","DOI":"10.1186\/s12859-016-1323-z","volume":"17","author":"GE Hoffman","year":"2016","unstructured":"Hoffman GE, Schadt EE. variancePartition: Interpreting drivers of variation in complex gene expression studies. BMC Bioinforma. 2016;17:483.","journal-title":"BMC Bioinforma"},{"key":"3724_CR34","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1093\/bioinformatics\/btaa687","volume":"37","author":"GE Hoffman","year":"2021","unstructured":"Hoffman GE, Roussos P. Dream: powerful differential expression analysis for repeated measures designs. Bioinformatics. 2021;37:192\u2013201.","journal-title":"Bioinformatics"},{"key":"3724_CR35","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1016\/j.jpsychires.2013.03.008","volume":"47","author":"HK M\u00fcller","year":"2013","unstructured":"M\u00fcller HK, Wegener G, Liebenberg N, Zarate JrCA, Popoli M, Elfving B. Ketamine regulates the presynaptic release machinery in the hippocampus. J Psychiatr Res. 2013;47:892\u20139.","journal-title":"J Psychiatr Res"},{"key":"3724_CR36","volume":"11","author":"X Ouyang","year":"2021","unstructured":"Ouyang X, Wang Z, Luo M, Wang M, Liu X, Chen J, et al. Ketamine ameliorates depressive-like behaviors in mice through increasing glucose uptake regulated by the ERK\/GLUT3 signaling pathway. Sci Rep. 2021;11:18181.","journal-title":"Sci Rep"},{"key":"3724_CR37","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1046\/j.1471-4159.2001.00300.x","volume":"77","author":"Y Dwivedi","year":"2001","unstructured":"Dwivedi Y, Rizavi H, Roberts R, Conley R, Tamminga C, Pandey G. Reduced activation and expression of ERK1\/2 MAP kinase in the post-mortem brain of depressed suicide subjects. J Neurochem. 2001;77:916\u201328.","journal-title":"J Neurochem"},{"key":"3724_CR38","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.jpsychires.2014.04.010","volume":"55","author":"GZ R\u00e9us","year":"2014","unstructured":"R\u00e9us GZ, Vieira FG, Abelaira HM, Michels M, Tomaz DB, dos Santos MAB, et al. MAPK signaling correlates with the antidepressant effects of ketamine. J Psychiatr Res. 2014;55:15\u201321.","journal-title":"J Psychiatr Res"},{"key":"3724_CR39","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1152\/jn.00326.2023","volume":"131","author":"LM Riggs","year":"2024","unstructured":"Riggs LM, Pereira EFR, Thompson SM, Gould TD. cAMP-dependent protein kinase signaling is required for (2R, 6R)-hydroxynorketamine to potentiate hippocampal glutamatergic transmission. J Neurophysiol. 2024;131:64\u201374.","journal-title":"J Neurophysiol"},{"key":"3724_CR40","doi-asserted-by":"crossref","first-page":"1833","DOI":"10.1038\/s41380-018-0083-8","volume":"24","author":"NH Wray","year":"2019","unstructured":"Wray NH, Schappi JM, Singh H, Senese NB, Rasenick MM. NMDAR-independent, cAMP-dependent antidepressant actions of ketamine. Mol Psychiatry. 2019;24:1833\u201343.","journal-title":"Mol Psychiatry"},{"key":"3724_CR41","doi-asserted-by":"crossref","first-page":"6197","DOI":"10.1007\/s12035-019-1524-3","volume":"56","author":"JQ Wang","year":"2019","unstructured":"Wang JQ, Mao L. The ERK pathway: Molecular mechanisms and treatment of depression. Mol Neurobiol. 2019;56:6197\u2013205.","journal-title":"Mol Neurobiol"},{"key":"3724_CR42","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/j.jad.2020.05.017","volume":"274","author":"K Feng","year":"2020","unstructured":"Feng K, Xu J-X, Chen X-X, Gao X-R, Huang L-L, Du A-Q, et al. Differential serum exosome microRNA profile in a stress-induced depression rat model. J Affect Disord. 2020;274:144\u201358.","journal-title":"J Affect Disord"},{"key":"3724_CR43","volume":"12","author":"K Burrows","year":"2022","unstructured":"Burrows K, Figueroa-Hall LK, Kuplicki R, Stewart JL, Alarbi AM, Ramesh R, et al. Neuronally-enriched exosomal microRNA-27b mediates acute effects of ibuprofen on reward-related brain activity in healthy adults: a randomized, placebo-controlled, double-blind trial. Sci Rep. 2022;12:861.","journal-title":"Sci Rep"},{"key":"3724_CR44","doi-asserted-by":"crossref","DOI":"10.1016\/j.gene.2020.144513","volume":"739","author":"MS Zastrozhin","year":"2020","unstructured":"Zastrozhin MS, Skryabin VY, Smirnov VV, Petukhov AE, Pankratenko EP, Zastrozhina AK, et al. Effects of plasma concentration of micro-RNA Mir-27b and CYP3A4*22 on equilibrium concentration of alprazolam in patients with anxiety disorders comorbid with alcohol use disorder. Gene. 2020;739:144513.","journal-title":"Gene"},{"key":"3724_CR45","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1038\/s41380-021-01040-1","volume":"27","author":"I Mantas","year":"2022","unstructured":"Mantas I, Saarinen M, Xu Z-QD, Svenningsson P. Update on GPCR-based targets for the development of novel antidepressants. Mol Psychiatry. 2022;27:534\u201358.","journal-title":"Mol Psychiatry"},{"key":"3724_CR46","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1007\/s00213-017-4586-9","volume":"234","author":"MZ Khan","year":"2017","unstructured":"Khan MZ, He L. Neuro-psychopharmacological perspective of Orphan receptors of Rhodopsin (class A) family of G protein-coupled receptors. Psychopharmacology (Berl). 2017;234:1181\u2013207.","journal-title":"Psychopharmacology (Berl)"},{"key":"3724_CR47","volume":"14","author":"C Zhang","year":"2024","unstructured":"Zhang C, K\u00fake\u013eov\u00e1 D, Sigrist H, Hengerer B, Kratzer RF, Mracek P, et al. Orphan receptor-GPR52 inverse agonist efficacy in ameliorating chronic stress-related deficits in reward motivation and phasic accumbal dopamine activity in mice. Transl Psychiatry. 2024;14:363.","journal-title":"Transl Psychiatry"},{"key":"3724_CR48","doi-asserted-by":"crossref","first-page":"e90134","DOI":"10.1371\/journal.pone.0090134","volume":"9","author":"H Komatsu","year":"2014","unstructured":"Komatsu H, Maruyama M, Yao S, Shinohara T, Sakuma K, Imaichi S, et al. Anatomical transcriptome of G protein-coupled receptors leads to the identification of a novel therapeutic candidate GPR52 for psychiatric disorders. PLoS ONE. 2014;9:e90134.","journal-title":"PLoS ONE"},{"key":"3724_CR49","volume":"29","author":"S Ali","year":"2024","unstructured":"Ali S, Wang P, Murphy RE, Allen JA, Zhou J. Orphan GPR52 as an emerging neurotherapeutic target. Drug Discov Today. 2024;29:103922.","journal-title":"Drug Discov Today"},{"key":"3724_CR50","doi-asserted-by":"crossref","DOI":"10.1038\/s41398-017-0085-3","volume":"8","author":"SL McElroy","year":"2018","unstructured":"McElroy SL, Winham SJ, Cuellar-Barboza AB, Colby CL, Ho AM-C, Sicotte H, et al. Bipolar disorder with binge eating behavior: a genome-wide association study implicates PRR5-ARHGAP8. Transl Psychiatry. 2018;8:40.","journal-title":"Transl Psychiatry"},{"key":"3724_CR51","doi-asserted-by":"publisher","unstructured":"Schmidt J, In\u00e1cio \u00c2, Ferreira JS, Serrenho D, Socodato R, Beltr\u00e3o N et al. Neuronal ARHGAP8 controls synapse structure and AMPA receptor-mediated synaptic transmission. bioRxiv 2024; https:\/\/doi.org\/10.1101\/2024.02.29.582472.","DOI":"10.1101\/2024.02.29.582472"},{"key":"3724_CR52","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1038\/mp.2016.174","volume":"22","author":"M-L Wong","year":"2017","unstructured":"Wong M-L, Arcos-Burgos M, Liu S, V\u00e9lez JI, Yu C, Baune BT, et al. The PHF21B gene is associated with major depression and modulates the stress response. Mol Psychiatry. 2017;22:1015\u201325.","journal-title":"Mol Psychiatry"},{"key":"3724_CR53","doi-asserted-by":"crossref","first-page":"136","DOI":"10.3389\/fnsyn.2010.00136","volume":"2","author":"PA Garay","year":"2010","unstructured":"Garay PA, McAllister AK. Novel roles for immune molecules in neural development: implications for neurodevelopmental disorders. Front Synaptic Neurosci. 2010;2:136.","journal-title":"Front Synaptic Neurosci"},{"key":"3724_CR54","volume":"14","author":"NG Caldito","year":"2023","unstructured":"Caldito NG. Role of tumor necrosis factor-alpha in the central nervous system: a focus on autoimmune disorders. Front Immunol. 2023;14:1213448.","journal-title":"Front Immunol"},{"key":"3724_CR55","volume":"16","author":"A Guo","year":"2022","unstructured":"Guo A, Lau CG. TNF-\u03b1 orchestrates experience-dependent plasticity of excitatory and inhibitory synapses in the anterior piriform cortex. Front Neurosci. 2022;16:824454.","journal-title":"Front Neurosci"},{"key":"3724_CR56","doi-asserted-by":"crossref","first-page":"733","DOI":"10.3390\/ijms17050733","volume":"17","author":"K Ma","year":"2016","unstructured":"Ma K, Zhang H, Baloch Z. Pathogenetic and therapeutic applications of tumor necrosis factor-\u03b1 (TNF-\u03b1) in major depressive disorder: a systematic review. Int J Mol Sci. 2016;17:733.","journal-title":"Int J Mol Sci"},{"key":"3724_CR57","first-page":"139","volume":"8","author":"Y Li","year":"2017","unstructured":"Li Y, Shen R, Wen G, Ding R, Du A, Zhou J, et al. Effects of ketamine on levels of inflammatory cytokines IL-6, IL-1\u03b2, and TNF-\u03b1 in the hippocampus of mice following acute or chronic administration. Front Pharm. 2017;8:139.","journal-title":"Front Pharm"},{"key":"3724_CR58","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1185748","volume":"14","author":"L Calvier","year":"2023","unstructured":"Calvier L, Drelich A, Hsu J, Tseng C-T, Mina Y, Nath A, et al. Circulating reelin promotes inflammation and modulates disease activity in acute and long COVID-19 cases. Front Immunol. 2023;14:1185748.","journal-title":"Front Immunol"},{"key":"3724_CR59","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.1111\/ejn.15971","volume":"57","author":"NK Morrill","year":"2023","unstructured":"Morrill NK, Li Q, Joly-Amado A, Weeber EJ, Nash KR. A novel reelin construct, R36, recovered behavioural deficits in the heterozygous reeler mouse. Eur J Neurosci. 2023;57:1657\u201370.","journal-title":"Eur J Neurosci"},{"key":"3724_CR60","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1177\/0269881112463468","volume":"27","author":"JT Rogers","year":"2013","unstructured":"Rogers JT, Zhao L, Trotter JH, Rusiana I, Peters MM, Li Q, et al. Reelin supplementation recovers sensorimotor gating, synaptic plasticity and associative learning deficits in the heterozygous reeler mouse. J Psychopharmacol. 2013;27:386\u201395.","journal-title":"J Psychopharmacol"},{"key":"3724_CR61","doi-asserted-by":"crossref","first-page":"2217","DOI":"10.1017\/S0033291721000441","volume":"51","author":"K Kendall","year":"2021","unstructured":"Kendall K, Van Assche E, Andlauer T, Choi K, Luykx J, Schulte E, et al. The genetic basis of major depression. Psychol Med. 2021;51:2217\u201330.","journal-title":"Psychol Med"},{"key":"3724_CR62","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1016\/j.neuron.2018.10.033","volume":"100","author":"SJ Engle","year":"2018","unstructured":"Engle SJ, Blaha L, Kleiman RJ. Best practices for translational disease modeling using human iPSC-derived neurons. Neuron. 2018;100:783\u201397.","journal-title":"Neuron"},{"key":"3724_CR63","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1038\/nature15526","volume":"527","author":"J Mertens","year":"2015","unstructured":"Mertens J, Wang Q-W, Kim Y, Yu DX, Pham S, Yang B, et al. Differential responses to lithium in hyperexcitable neurons from patients with bipolar disorder. Nature. 2015;527:95\u201399.","journal-title":"Nature"}],"container-title":["Translational Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41398-025-03724-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41398-025-03724-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41398-025-03724-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,15]],"date-time":"2025-12-15T13:07:00Z","timestamp":1765804020000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41398-025-03724-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,18]]},"references-count":63,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["3724"],"URL":"https:\/\/doi.org\/10.1038\/s41398-025-03724-6","relation":{},"ISSN":["2158-3188"],"issn-type":[{"value":"2158-3188","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,18]]},"assertion":[{"value":"16 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 September 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 October 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 November 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Dr. Zarate is listed as a co-inventor on a patent for the use of ketamine in major depression and suicidal ideation; as a co-inventor on a patent for the use of (2\u2009\n                      R\n                      ,6\u2009\n                      R\n                      )-hydroxynorketamine, (\n                      S\n                      )-dehydronorketamine, and other stereoisomeric dehydroxylated and hydroxylated metabolites of (\n                      R,S\n                      )-ketamine in the treatment of depression and neuropathic pain; and as a co-inventor on a patent application for the use of (2\u2009\n                      R\n                      ,6\u2009\n                      R\n                      )-hydroxynorketamine and (2\n                      S\n                      ,6\n                      S\n                      )-hydroxynorketamine in the treatment of depression, anxiety, anhedonia, suicidal ideation, and post-traumatic stress disorder. He has assigned his patent rights to the U.S. government but will share a percentage of any royalties that may be received by the government. Dr. Kadriu is presently employed full-time by and holds shares in Bristol Myers Squibb. He has previously been employed by Johnson & Johnson and Jazz Pharmaceuticals, where he also maintains share ownership. All other authors have no conflict of interest to disclose, financial or otherwise.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"All participants enrolled in the parent clinical trial at the National Institute of Mental Health (NIMH) (NCT02484456) provided written informed consent before taking part in the study, which was approved by the NIH Institutional Review Board.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics"}}],"article-number":"524"}}